|
MechanismNorepinephrine reuptake inhibitors [+2] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
A Prospective, Randomized, Double-blinded, Active-control, 3-Treatment Arm, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of On-demand Therapy with CDFR0812-15/50mg Compared to On-demand Therapy with Single-drug Administration of Clomipramine HCl 15mg or Sildenafil citrate 50mg in Male Patients Diagnosed with Premature Ejaculation
A Prospective, Randomized, Double-blinded, Active-control, 3-Treatment Arm, Parallel, Multi-center, Phase 2 Trial to Evaluate Safety and Efficacy With CDFR0812-15/25mg and CDFR0812-15/50mg Compared to Clomipramine HCl 15mg in Male Patients Diagnosed With Premature Ejaculation
The purpose of this study is to evaluate the safety and efficacy of on-demand therapy with CDFR0812-15/25mg and CDFR0812-15/50mg compared to on-demand therapy with single-drug administration of Clomipramine HCl 15mg in Korean Male Patients Diagnosed with Premature Ejaculation
100 Clinical Results associated with PDE5A x SERT x NET
100 Translational Medicine associated with PDE5A x SERT x NET
0 Patents (Medical) associated with PDE5A x SERT x NET